{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-008015","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.099832+00:00","generated_at":"2026-06-06T14:51:35.520287+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial","bullets":["CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.","List price (WAC) set at $249.99 per 3mL vial; company committed to reduce price if Part B reimbursement is granted.","Reiterates inpatient launch target of April 15, 2024; outpatient launch target of July 1, 2024, contingent on CMS TDAPA approval.","Company will notify CMS to adjust inpatient NTAP reimbursement now that a WAC price is established."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-008015","json":"https://secwatch.observer/filing/0001213900-24-008015.json","markdown":"https://secwatch.observer/filing/0001213900-24-008015.md","text":"https://secwatch.observer/filing/0001213900-24-008015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/0001213900-24-008015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/ea192430-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:51:35.520287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}